Top

Reactions Weekly

Published in:

01-11-2023 | Trastuzumab | Case report

Trastuzumab-deruxtecan

Lack of efficacy: case report

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Li BT, et al. 1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02. Annals of Oncology 34 (Suppl. 2): S762-S763 abstr. 1321MO, Oct 2023. Available from: URL: http://doi.org/10.1016/j.annonc.2023.09.2354 [abstract]

Title: Trastuzumab-deruxtecan
Lack of efficacy: case report
Publication date: 01-11-2023
Publisher: Springer International Publishing
Keywords: Trastuzumab
NSCLC
NSCLC
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-49343-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Trastuzumab-deruxtecan

Lack of efficacy: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Ciprofloxacin

Clonazepam/cobalamin/prednisolone

Doxycycline

Durvalumab

Aspirin/sodium-bicarbonate

Favipiravir